Dinutuximab 联合化疗、手术和干细胞移植治疗新诊断的高危神经母细胞瘤儿童
Dinutuximab 添加到新诊断高危神经母细胞瘤儿童强化多模式治疗中的 3 期研究
This phase III trial tests how well the addition of dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy works for treating children with newly diagnosed high-risk neuroblastoma. Dinutuximab is a monoclonal antibody that binds to a molecule called GD2, which is found on the surface of neuroblastoma cells, but is not present on many healthy or normal cells in the body. When dinutuximab binds to the neuroblastoma cells, it helps signal the immune system to kill the tumor cells. This helps the cells of the immune system kill the cancer cells, this is a type of immunotherapy. When chemotherapy and immunotherapy are given together, during the same treatment cycle, it is called chemoimmunotherapy. This clinical trial randomly assigns patients to receive either standard chemotherapy and surgery or chemoimmunotherapy (chemotherapy plus dinutuximab) and surgery during Induction therapy. Chemotherapy drugs administered during Induction include, cyclophosphamide, topotecan, cisplatin, etoposide, vincristine, and doxorubicin. These drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing or by stopping them from spreading. Upon completion of 5 cycles of Induction therapy, a disease evaluation is completed to determine how well the treatment worked. If the tumor responds to therapy, patients receive a tandem transplantation with stem cell rescue. If the tumor has little improvement or worsens, patients receive chemoimmunotherapy on Extended Induction. During Extended Induction, dinutuximab is given with irinotecan, temozolomide. Patients with a good response to therapy move on to Consolidation therapy, when very high doses of chemotherapy are given at two separate points to kill any remaining cancer cells. Following, transplant, radiation therapy is given to the site where the cancer originated (primary site) and to any other areas that are still active at the end of Induction. The final stage of therapy is Post-Consolidation. During Post-Consolidation, dinutuximab is given with isotretinoin, with the goal of maintaining the response achieved with the previous therapy. Adding dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy may be better at treating children with newly diagnosed high-risk neuroblastoma.
研究概览
地位
条件
干预/治疗
- 药品:Carboplatin
- 药品:Cyclophosphamide
- 药品:Cisplatin
- 程序:Bone Marrow Biopsy
- 药品:Doxorubicin
- 药品:Vincristine
- 程序:Magnetic Resonance Imaging
- 程序:Echocardiography Test
- 程序:Multigated Acquisition Scan
- 程序:Bone Marrow Aspiration
- 药品:Etoposide
- 程序:Computed Tomography
- 药品:Topotecan
- 辐射:Radiation Therapy
- 程序:Biospecimen Collection
- 其他:Survey Administration
- 药品:Melphalan
- 药品:Irinotecan
- 药品:Thiotepa
- 生物:Dinutuximab
- 程序:FDG-Positron Emission Tomography and Computed Tomography Scan
- 程序:Hematopoietic Cell Transplantation
- 药品:Isotretinoin
- 程序:Leukapheresis
- 程序:Radionuclide Imaging
- 药品:Temozolomide
- 程序:Tumor Resection
详细说明
PRIMARY OBJECTIVE:
I. To determine if the event-free survival (EFS) of patients with newly diagnosed high-risk neuroblastoma assigned to early chemoimmunotherapy during Induction differs from that of patients who are not assigned to treatment that includes early chemoimmunotherapy.
SECONDARY OBJECTIVES:
I. To determine if early chemoimmunotherapy during Induction therapy improves end of Induction (EOI) response rates and overall survival (OS) for patients with newly diagnosed high-risk neuroblastoma.
II. To determine response rates, EFS, and OS following an Extended Induction regimen with chemoimmunotherapy in patients with progressive disease or a poor response to Induction therapy.
III. To compare the toxicities experienced by patients treated with chemoimmunotherapy during Induction versus those experienced by patients treated with standard Induction and to describe toxicities experienced during Extended Induction.
IV. To determine GD2 expression on tumor tissue and tumor cells in bone marrow and assess for associations with response and outcome.
EXPLORATORY OBJECTIVES:
I. To describe the association between tumor and host factors and outcomes in patients receiving protocol therapy.
II. To evaluate circulating biomarkers and markers of minimal residual disease at baseline and during therapy, and assess for associations with response and outcome.
III. To compare patterns of failure between patients treated with and without dinutuximab during induction.
IV. To determine the effect of telomere maintenance mechanisms on end of Induction response rates, EFS, and OS.
V. To explore the impact of high-risk neuroblastoma (HRNBL) and its therapy, including the addition of dinutuximab to Induction chemotherapy, on functional and quality of life outcomes in patients with HRNBL, as measured by caregiver (parent/legal guardian) and patient questionnaires.
VI. To describe the adequacy of diagnostic biopsy specimens, including those obtained by percutaneous core needle biopsy.
VII. To explore the associations between family-reported adverse social determinants of health and both clinical outcomes and biology.
VIII. To develop and validate deep learning predictors of Induction response based on diagnostic MIBG scans. (Imaging Objective) IX. To compare institutional versus central determination of overall response, individual response components (primary tumor, soft tissue and bone metastatic disease, and bone marrow metastatic disease), and poor end of induction response (PEIR) and good end of induction response (GEIR) determination. (Imaging Objective) X. To describe late toxicities (including impaired organ function, neuropsychiatric toxicity, and incidence of secondary malignancy) in patients treated with dinutuximab during Induction or Extended Induction to late toxicities in patients who have not received dinutuximab during these phases of therapy.
XI. To evaluate whether reduced dose radiotherapy to the primary site clinical target volume (CTV) in patients with complete response of the primary site at EOI results in comparable local control relative to historical cohorts.
XII. To compare post-transplant complications between treatment arms, and assess for associations with outcome.
XIII. To assess for associations between EOI response (including good end of Induction response [GEIR] and poor end of Induction response [PEIR]) and individual response components (primary tumor, soft tissue and bone metastatic disease, and bone marrow metastatic disease) with outcome (EFS and OS).
XIV. To describe and compare the changes in image-defined risk factors (IDRFs) between patients treated with and without dinutuximab during Induction and associate with surgical outcomes and local failure rates following primary tumor resection.
XV. To bank serial samples of blood, bone marrow, and tumor tissue for future research.
OUTLINE: Patients receive Induction cycle 1 and are then randomized to 1 of 2 treatment arms.
INDUCTION CYCLE 1: Patients receive cyclophosphamide intravenously (IV) over 30 minutes and topotecan IV over 30 minutes on days 1-5 in the absence of unacceptable toxicity.
ARM A:
INDUCTION CYCLES 2-5: Patients receive cyclophosphamide IV over 30 minutes and topotecan IV over 30 minutes on days 1-5 of cycle 2 in the absence of unacceptable toxicity. Patients then undergo stem cell harvest via apheresis. Patients then receive cisplatin IV over 4 hours and etoposide IV over 2 hours on days 1-3 of cycles 3 and 5, and vincristine IV on day 1, doxorubicin IV over 15 minutes, and cyclophosphamide IV over 1 hour on days 1-2 of cycle 4 in the absence of unacceptable toxicity. Patients undergo primary tumor resection after Induction cycle 4 or 5. Following Induction cycle 5, patients undergo testing to determine response to Induction therapy. Patients with a good tumor response proceed to Consolidation, while patients with a poor tumor response proceed to Extended Induction.
EXTENDED INDUCTION: Patients with a poor tumor response or progression during Induction receive temozolomide orally (PO), via nasogastric tube (NG), or via gastric tube (G-tube) on days 1-5, irinotecan IV over 90 minutes on days 1-5, and dinutuximab IV over 10 hours. Treatment repeats every 21 days for up to a maximum of 6 cycles in the absence of disease progression or unacceptable toxicity. If at any time during Extended Induction testing shows a good tumor response, patients proceed to Consolidation. If after 6 cycles of Extended Induction or if at any time progression is noted, patients are removed from the study.
CONSOLIDATION: Patients undergo two autologous hematopoietic stem cell transplantations (HSCTs) during Consolidation. Patients receive thiotepa IV over 2 hours on days -7 to -5 and cyclophosphamide IV over 1 hour on days -5 to -2 during HSCT 1. Patients then receive stem cell infusion IV on day 0. Between 6 and 10 weeks after stem cell infusion, patients receive melphalan IV over 30 minutes on days -7 to -5, etoposide IV over 24 hours on days -7 to -4, and carboplatin over 24 hours on days -7 to -4 during HSCT 2. Patients receive stem cell infusion IV on day 0. Between day +42 and day +80 after HSCT 2. Patients receive radiation daily for 12 treatments in the absence of disease progression or unacceptable toxicity.
POST CONSOLIDATION: Patients receive dinutuximab IV over 10 hours on days 4-7 and isotretinoin PO twice daily (BID) on days 11-24 of cycles 1-5. Treatment repeats every 28 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive isotretinoin PO BID on days 15-28 for 1 additional cycle, cycle 6.
Patients undergo blood and urine sample collection, echocardiogram (ECHO) or multigated acquisition scan (MUGA), bone marrow aspiration and/or biopsy, computed tomography (CT) scan, magnetic resonance imaging (MRI), iodine-123 meta-iodobenzylguanidine (I-MIBG) scan and possible fluorodeoxyglucose position emission tomography (FDG-PET) scan throughout the study.
ARM B:
INDUCTION CYCLES 2-5: Patients receive cyclophosphamide IV over 30 minutes, topotecan IV over 30 minutes on days 1-5, and dinutuximab IV over 10 hours on days 2-5 of cycle 2 in the absence of unacceptable toxicity. Patients then undergo stem cell harvest via apheresis. Patients receive cisplatin IV over 4 hours and etoposide IV over 2 hours on days 1-3 and dinutuximab IV over 10 hours on days 2-5 of cycles 3 and 5, and vincristine IV on day 1, doxorubicin IV over 15 minutes, and cyclophosphamide IV over 1 hour on days 1-2, and dinutuximab IV over 10 hours on days 2-5 of cycle 4 in the absence of unacceptable toxicity. Patients undergo primary tumor resection after Induction cycle 4 or 5. Following Induction cycle 5, patients undergo testing to determine response to Induction therapy. Patients with a good tumor response proceed to Consolidation, while patients with a poor tumor response proceed to Extended Induction.
EXTENDED INDUCTION: Patients with a poor tumor response or progression during Induction receive temozolomide PO, via NG tube, or via G-tube on days 1-5, irinotecan IV over 90 minutes on days 1-5, and dinutuximab IV over 10 hours. Treatment repeats every 21 days for up to a maximum of 6 cycles in the absence of disease progression or unacceptable toxicity. If at any time during Extended Induction testing shows a good tumor response, patients proceed to Consolidation. If after 6 cycles of Extended Induction or if at any time progression is noted, patients are removed from the study.
CONSOLIDATION: Patients undergo two autologous HSCTs during Consolidation. Patients receive thiotepa IV over 2 hours on days -7 to -5 and cyclophosphamide IV over 1 hour on days -5 to -2 during HSCT 1. Patients then receive stem cell infusion IV on day 0. Between 6 and 10 weeks after stem cell infusion patients receive melphalan IV over 30 minutes on days -7 to -5, etoposide IV over 24 hours on days -7 to -4, and carboplatin over 24 hours on days -7 to -4 during HSCT 2. Patients receive stem cell infusion IV on day 0. Between day +42 and day +80 after HSCT 2, patients receive radiation daily for 12 treatments in the absence of disease progression or unacceptable toxicity.
POST CONSOLIDATION: Patients receive dinutuximab IV over 10 hours on days 4-7 and isotretinoin PO BID on days 11-24 of cycles 1-5. Treatment repeats every 28 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive isotretinoin PO BID on days 15-28 for 1 additional cycle, cycle 6.
Patients undergo blood and urine sample collection, ECHO or MUGA, bone marrow aspiration and/or biopsy, CT scan, MRI, I-MIBG scan and possible FDG-PET scan throughout the study.
After completion of study treatment, patients are followed up at 3, 6, 9,12, 15, 18, 24, 30, 36, 42, 48, 54, and 60 months and then periodically for up to 10 years from enrollment.
研究类型
注册 (估计的)
阶段
- 第三阶段
联系人和位置
学习地点
-
-
-
Québec、加拿大、G1V 4G2
- 招聘中
- CHU de Quebec-Centre Hospitalier de l'Universite Laval (CHUL)
-
首席研究员:
- Bruno Michon
-
接触:
- Site Public Contact
- 电话号码:418-525-4444
- 邮箱:rechclinique@crchudequebec.ulaval.ca
-
-
Alberta
-
Calgary、Alberta、加拿大、T3B 6A8
- 招聘中
- Alberta Children's Hospital
-
接触:
- Site Public Contact
- 电话号码:403-220-6898
- 邮箱:research4kids@ucalgary.ca
-
首席研究员:
- Victor A. Lewis
-
Edmonton、Alberta、加拿大、T6G 2B7
- 招聘中
- University of Alberta Hospital
-
接触:
- Site Public Contact
- 电话号码:780-407-8798
- 邮箱:pedsoncologyresearch@ahs.ca
-
首席研究员:
- Sarah J. McKillop
-
-
British Columbia
-
Vancouver、British Columbia、加拿大、V6H 3V4
- 招聘中
- British Columbia Children's Hospital
-
接触:
- Site Public Contact
- 电话号码:6477 604-875-2345
-
首席研究员:
- Rebecca J. Deyell
-
-
Manitoba
-
Winnipeg、Manitoba、加拿大、R3E 0V9
- 招聘中
- CancerCare Manitoba
-
接触:
- Site Public Contact
- 电话号码:866-561-1026
- 邮箱:ctu_web@cancercare.mb.ca
-
首席研究员:
- Stephanie M. Villeneuve
-
-
Newfoundland and Labrador
-
St. John's、Newfoundland and Labrador、加拿大、A1B 3V6
- 招聘中
- Janeway Child Health Centre
-
首席研究员:
- Lisa A. Goodyear
-
接触:
- Site Public Contact
- 电话号码:709-777-8727
- 邮箱:beverlyj.mitchell@easternhealth.ca
-
-
Nova Scotia
-
Halifax、Nova Scotia、加拿大、B3K 6R8
- 招聘中
- IWK Health Centre
-
接触:
- Site Public Contact
- 电话号码:902-470-8520
- 邮箱:Research@iwk.nshealth.ca
-
首席研究员:
- Chelsea Ash
-
-
Ontario
-
Hamilton、Ontario、加拿大、L8N 3Z5
- 招聘中
- McMaster Children's Hospital at Hamilton Health Sciences
-
接触:
- Site Public Contact
- 电话号码:905-521-2100
-
首席研究员:
- Uma H. Athale
-
London、Ontario、加拿大、N6A 5W9
- 招聘中
- Children's Hospital
-
接触:
- Site Public Contact
- 电话号码:519-685-8306
-
首席研究员:
- Shayna M. Zelcer
-
Ottawa、Ontario、加拿大、K1H 8L1
- 招聘中
- Children's Hospital of Eastern Ontario
-
接触:
- Site Public Contact
- 电话号码:613-737-7600
-
首席研究员:
- Donna L. Johnston
-
Toronto、Ontario、加拿大、M5G 1X8
- 招聘中
- Hospital for Sick Children
-
接触:
- Site Public Contact
- 电话号码:416-813-7654
- 邮箱:ask.CRS@sickkids.ca
-
首席研究员:
- Daniel A. Morgenstern
-
-
Quebec
-
Montreal、Quebec、加拿大、H3H 1P3
- 招聘中
- The Montreal Children's Hospital of the MUHC
-
接触:
- Site Public Contact
- 电话号码:514-412-4445
- 邮箱:info@thechildren.com
-
首席研究员:
- Stephanie Mourad
-
Montreal、Quebec、加拿大、H3T 1C5
- 招聘中
- Centre Hospitalier Universitaire Sainte-Justine
-
首席研究员:
- Monia Marzouki
-
接触:
- Site Public Contact
- 电话号码:514-345-4931
- 邮箱:yvan.samson@umontreal.ca
-
Sherbrooke、Quebec、加拿大、J1H 5N4
- 招聘中
- Centre Hospitalier Universitaire de Sherbrooke-Fleurimont
-
接触:
- Site Public Contact
- 电话号码:819-820-6480
- 邮箱:crcinformation.chus@ssss.gouv.qc.ca
-
首席研究员:
- Stephanie Vairy
-
-
Saskatchewan
-
Saskatoon、Saskatchewan、加拿大、S7N 0W8
- 招聘中
- Jim Pattison Children's Hospital
-
首席研究员:
- Kathleen Felton
-
接触:
- Site Public Contact
- 电话号码:306-655-3544
- 邮箱:Jessica.Marien@saskhealthauthority.ca
-
-
-
-
Auckland
-
Grafton、Auckland、新西兰、1145
- 招聘中
- Starship Children's Hospital
-
首席研究员:
- Andrew C. Wood
-
接触:
- Site Public Contact
- 电话号码:0800 728 436
-
-
-
-
-
San Juan、波多黎各、00926
- 招聘中
- University Pediatric Hospital
-
接触:
- Site Public Contact
- 电话号码:787-474-0333
-
首席研究员:
- Maria E. Echevarria
-
-
-
-
New South Wales
-
Randwick、New South Wales、澳大利亚、2031
- 招聘中
- Sydney Children's Hospital
-
首席研究员:
- Draga Barbaric
-
接触:
- Site Public Contact
- 电话号码:(02) 9382-1721
-
Westmead、New South Wales、澳大利亚、2145
- 招聘中
- The Children's Hospital at Westmead
-
接触:
- Site Public Contact
- 电话号码:61-2-9845 1400
-
首席研究员:
- Bhavna Padhye
-
-
Queensland
-
South Brisbane、Queensland、澳大利亚、4101
- 招聘中
- Queensland Children's Hospital
-
首席研究员:
- Steven A. Foresto
-
接触:
- Site Public Contact
- 电话号码:61 7 3068 1111
-
-
Victoria
-
Parkville、Victoria、澳大利亚、3052
- 招聘中
- Royal Children's Hospital
-
首席研究员:
- Martin A. Campbell
-
接触:
- Site Public Contact
- 电话号码:61 3 9345 5656
- 邮箱:Jordan.Hansford@rch.org.au
-
-
Western Australia
-
Perth、Western Australia、澳大利亚、6009
- 招聘中
- Perth Children's Hospital
-
接触:
- Site Public Contact
- 邮箱:helpdesk@childrensoncologygroup.org
-
首席研究员:
- Michelle Ng
-
-
-
-
Alabama
-
Birmingham、Alabama、美国、35233
- 招聘中
- Children's Hospital of Alabama
-
接触:
- Site Public Contact
- 电话号码:205-638-9285
- 邮箱:oncologyresearch@peds.uab.edu
-
首席研究员:
- Elizabeth D. Alva
-
Mobile、Alabama、美国、36604
- 招聘中
- USA Health Strada Patient Care Center
-
接触:
- Site Public Contact
- 电话号码:800-388-8721
-
首席研究员:
- Hamayun Imran
-
-
Arizona
-
Mesa、Arizona、美国、85202
- 招聘中
- Banner Children's at Desert
-
接触:
- Site Public Contact
- 电话号码:480-412-3100
-
首席研究员:
- Joseph C. Torkildson
-
Phoenix、Arizona、美国、85016
- 招聘中
- Phoenix Childrens Hospital
-
接触:
- Site Public Contact
- 电话号码:602-546-0920
-
首席研究员:
- Alok K. Kothari
-
Tucson、Arizona、美国、85719
- 招聘中
- Banner University Medical Center - Tucson
-
接触:
- Site Public Contact
- 邮箱:UACC-IIT@uacc.arizona.edu
-
首席研究员:
- Monica M. Davini
-
-
Arkansas
-
Little Rock、Arkansas、美国、72202-3591
- 招聘中
- Arkansas Children's Hospital
-
首席研究员:
- Michael W. Bishop
-
接触:
- Site Public Contact
- 电话号码:501-364-7373
-
-
California
-
Downey、California、美国、90242
- 招聘中
- Kaiser Permanente Downey Medical Center
-
接触:
- Site Public Contact
- 电话号码:626-564-3455
-
首席研究员:
- Robert M. Cooper
-
Duarte、California、美国、91010
- 招聘中
- City of Hope Comprehensive Cancer Center
-
接触:
- Site Public Contact
- 电话号码:800-826-4673
- 邮箱:becomingapatient@coh.org
-
首席研究员:
- Hung C. Tran
-
Loma Linda、California、美国、92354
- 招聘中
- Loma Linda University Medical Center
-
接触:
- Site Public Contact
- 电话号码:909-558-4050
-
首席研究员:
- Albert Kheradpour
-
Long Beach、California、美国、90806
- 招聘中
- Miller Children's and Women's Hospital Long Beach
-
接触:
- Site Public Contact
- 电话号码:562-933-5600
-
首席研究员:
- Jacqueline N. Casillas
-
Los Angeles、California、美国、90027
- 招聘中
- Children's Hospital Los Angeles
-
接触:
- Site Public Contact
- 电话号码:323-361-4110
-
首席研究员:
- Araz Marachelian
-
Los Angeles、California、美国、90048
- 招聘中
- Cedars-Sinai Medical Center
-
首席研究员:
- Fataneh (Fae) Majlessipour
-
接触:
- Site Public Contact
- 电话号码:310-423-2133
- 邮箱:Cancer.trial.info@cshs.org
-
Los Angeles、California、美国、90095
- 招聘中
- Mattel Children's Hospital UCLA
-
接触:
- Site Public Contact
- 电话号码:310-825-6708
-
首席研究员:
- Satiro N. De Oliveira
-
Madera、California、美国、93636
- 招聘中
- Valley Children's Hospital
-
接触:
- Site Public Contact
- 电话号码:559-353-3000
- 邮箱:Research@valleychildrens.org
-
首席研究员:
- Ruetima Titapiwatanakun
-
Oakland、California、美国、94611
- 招聘中
- Kaiser Permanente-Oakland
-
接触:
- Site Public Contact
- 电话号码:877-642-4691
- 邮箱:Kpoct@kp.org
-
首席研究员:
- Aarati V. Rao
-
Oakland、California、美国、94609
- 招聘中
- UCSF Benioff Children's Hospital Oakland
-
首席研究员:
- Jennifer G. Michlitsch
-
接触:
- Site Public Contact
- 电话号码:510-428-3264
- 邮箱:PedOncRschOAK@ucsf.edu
-
Orange、California、美国、92868
- 招聘中
- Children's Hospital of Orange County
-
接触:
- Site Public Contact
- 电话号码:714-509-8646
- 邮箱:oncresearch@choc.org
-
首席研究员:
- Elyssa M. Rubin
-
Palo Alto、California、美国、94304
- 招聘中
- Lucile Packard Children's Hospital Stanford University
-
接触:
- Site Public Contact
- 电话号码:800-694-0012
- 邮箱:ccto-office@stanford.edu
-
首席研究员:
- Jay Michael S. Balagtas
-
Sacramento、California、美国、95817
- 招聘中
- University of California Davis Comprehensive Cancer Center
-
接触:
- Site Public Contact
- 电话号码:916-734-3089
-
首席研究员:
- Marcio H. Malogolowkin
-
Sacramento、California、美国、95816
- 招聘中
- Sutter Medical Center Sacramento
-
接触:
- Site Public Contact
- 邮箱:clinicalresearch@sutterhealth.org
-
首席研究员:
- Sandra Baril
-
San Diego、California、美国、92123
- 招聘中
- Rady Children's Hospital - San Diego
-
接触:
- Site Public Contact
- 电话号码:858-966-5934
-
首席研究员:
- William D. Roberts
-
San Francisco、California、美国、94158
- 招聘中
- UCSF Medical Center-Mission Bay
-
接触:
- Site Public Contact
- 电话号码:877-827-3222
- 邮箱:cancertrials@ucsf.edu
-
首席研究员:
- Arun A. Rangaswami
-
-
Colorado
-
Aurora、Colorado、美国、80045
- 招聘中
- Children's Hospital Colorado
-
首席研究员:
- Navin R. Pinto
-
接触:
- Site Public Contact
- 电话号码:303-764-5056
- 邮箱:josh.b.gordon@nsmtp.kp.org
-
-
Connecticut
-
Hartford、Connecticut、美国、06106
- 招聘中
- Connecticut Children's Medical Center
-
接触:
- Site Public Contact
- 电话号码:860-545-9981
-
首席研究员:
- Michael S. Isakoff
-
New Haven、Connecticut、美国、06520
- 招聘中
- Yale University
-
接触:
- Site Public Contact
- 电话号码:203-785-5702
- 邮箱:canceranswers@yale.edu
-
首席研究员:
- Farzana Pashankar
-
-
Delaware
-
Wilmington、Delaware、美国、19803
- 招聘中
- Alfred I duPont Hospital for Children
-
接触:
- Site Public Contact
- 电话号码:302-651-5572
- 邮箱:Allison.bruce@nemours.org
-
首席研究员:
- Sridhi Patel
-
-
District of Columbia
-
Washington D.C.、District of Columbia、美国、20010
- 招聘中
- Children's National Medical Center
-
首席研究员:
- Jeffrey S. Dome
-
接触:
- Site Public Contact
- 电话号码:202-476-2800
- 邮箱:OncCRC_OnCall@childrensnational.org
-
-
Florida
-
Fort Lauderdale、Florida、美国、33316
- 招聘中
- Broward Health Medical Center
-
接触:
- Site Public Contact
- 电话号码:302-651-5572
- 邮箱:Allison.bruce@nemours.org
-
首席研究员:
- Hector M. Rodriguez-Cortes
-
Fort Myers、Florida、美国、33908
- 招聘中
- Golisano Children's Hospital of Southwest Florida
-
接触:
- Site Public Contact
- 电话号码:239-343-5333
- 邮箱:molly.arnstrom@leehealth.org
-
首席研究员:
- Emad K. Salman
-
Gainesville、Florida、美国、32610
- 招聘中
- UF Health Cancer Institute - Gainesville
-
接触:
- Site Public Contact
- 电话号码:352-273-8010
- 邮箱:cancer-center@ufl.edu
-
首席研究员:
- Brian Stover
-
Hollywood、Florida、美国、33021
- 招聘中
- Memorial Regional Hospital/Joe DiMaggio Children's Hospital
-
接触:
- Site Public Contact
- 电话号码:954-265-1847
- 邮箱:OHR@mhs.net
-
首席研究员:
- Iftikhar Hanif
-
Jacksonville、Florida、美国、32207
- 招聘中
- Nemours Children's Clinic-Jacksonville
-
接触:
- Site Public Contact
- 电话号码:302-651-5572
- 邮箱:Allison.bruce@nemours.org
-
首席研究员:
- Sridhi Patel
-
Miami、Florida、美国、33155
- 招聘中
- Nicklaus Children's Hospital
-
接触:
- Site Public Contact
- 电话号码:888-624-2778
-
首席研究员:
- Ziad A. Khatib
-
Miami、Florida、美国、33136
- 招聘中
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
接触:
- Site Public Contact
- 电话号码:305-243-2647
-
首席研究员:
- Meghan McCormick
-
Orlando、Florida、美国、32806
- 招聘中
- Arnold Palmer Hospital for Children
-
接触:
- Site Public Contact
- 电话号码:321-841-5357
- 邮箱:Jennifer.spinelli@orlandohealth.com
-
首席研究员:
- Zhongbo Hu
-
Orlando、Florida、美国、32827
- 招聘中
- Nemours Children's Hospital
-
接触:
- Site Public Contact
- 电话号码:302-651-5572
- 邮箱:Allison.bruce@nemours.org
-
首席研究员:
- Sridhi Patel
-
Orlando、Florida、美国、32803
- 招聘中
- AdventHealth Orlando
-
接触:
- Site Public Contact
- 电话号码:407-303-2090
- 邮箱:FH.Cancer.Research@flhosp.org
-
首席研究员:
- Fouad M. Hajjar
-
St. Petersburg、Florida、美国、33701
- 招聘中
- Johns Hopkins All Children's Hospital
-
接触:
- Site Public Contact
- 电话号码:727-767-4784
- 邮箱:Ashley.Repp@jhmi.edu
-
首席研究员:
- Jennifer B. Dean
-
West Palm Beach、Florida、美国、33407
- 招聘中
- Saint Mary's Medical Center
-
首席研究员:
- Matthew D. Ramirez
-
接触:
- Site Public Contact
- 电话号码:561-822-4745
-
-
Georgia
-
Atlanta、Georgia、美国、30329
- 招聘中
- Children's Healthcare of Atlanta - Arthur M Blank Hospital
-
首席研究员:
- William T. Cash
-
接触:
- Site Public Contact
- 电话号码:404-785-0232
- 邮箱:Olivia.Floyd@choa.org
-
Savannah、Georgia、美国、31404
- 招聘中
- Memorial Health University Medical Center
-
接触:
- Site Public Contact
- 电话号码:912-350-7887
- 邮箱:Lorraine.OHara@hcahealthcare.com
-
首席研究员:
- James N. Yarnall
-
-
Hawaii
-
Honolulu、Hawaii、美国、96826
- 招聘中
- Kapiolani Medical Center for Women and Children
-
接触:
- Site Public Contact
- 电话号码:808-983-6090
-
首席研究员:
- Wade T. Kyono
-
-
Illinois
-
Chicago、Illinois、美国、60611
- 招聘中
- Lurie Children's Hospital-Chicago
-
接触:
- Site Public Contact
- 电话号码:773-880-4562
-
首席研究员:
- Elizabeth A. Sokol
-
Chicago、Illinois、美国、60637
- 招聘中
- University of Chicago Comprehensive Cancer Center
-
接触:
- Site Public Contact
- 电话号码:773-702-8222
- 邮箱:cancerclinicaltrials@bsd.uchicago.edu
-
首席研究员:
- Ami V. Desai
-
Chicago、Illinois、美国、60612
- 招聘中
- University of Illinois
-
接触:
- Site Public Contact
- 电话号码:312-355-3046
-
首席研究员:
- Dipti S. Dighe
-
Oak Lawn、Illinois、美国、60453
- 招聘中
- Advocate Children's Hospital-Oak Lawn
-
接触:
- Site Public Contact
- 电话号码:847-723-7570
-
首席研究员:
- Rebecca E. McFall
-
Park Ridge、Illinois、美国、60068
- 招聘中
- Advocate Children's Hospital-Park Ridge
-
接触:
- Site Public Contact
- 邮箱:helpdesk@childrensoncologygroup.org
-
首席研究员:
- Rebecca E. McFall
-
Peoria、Illinois、美国、61637
- 招聘中
- OSF Children's Hospital of Illinois
-
首席研究员:
- Prerna Kumar
-
接触:
- Site Public Contact
- 电话号码:309-624-4945
- 邮箱:ChildrensHospitalofIllinois@osfhealthcare.org
-
Springfield、Illinois、美国、62702
- 招聘中
- Southern Illinois University School of Medicine
-
接触:
- Site Public Contact
- 电话号码:217-545-7929
-
首席研究员:
- Gregory P. Brandt
-
-
Indiana
-
Indianapolis、Indiana、美国、46202
- 招聘中
- Riley Hospital for Children
-
接触:
- Site Public Contact
- 电话号码:800-248-1199
-
首席研究员:
- Marissa Just
-
Indianapolis、Indiana、美国、46260
- 招聘中
- Ascension Saint Vincent Indianapolis Hospital
-
接触:
- Site Public Contact
- 电话号码:317-338-2194
- 邮箱:research@stvincent.org
-
首席研究员:
- Bassem I. Razzouk
-
-
Iowa
-
Des Moines、Iowa、美国、50309
- 招聘中
- Blank Children's Hospital
-
接触:
- Site Public Contact
- 电话号码:515-241-8912
- 邮箱:samantha.mallory@unitypoint.org
-
首席研究员:
- Samantha L. Mallory
-
Iowa City、Iowa、美国、52242
- 招聘中
- University of Iowa/Holden Comprehensive Cancer Center
-
接触:
- Site Public Contact
- 电话号码:800-237-1225
-
首席研究员:
- Andrew P. Groves
-
-
Kansas
-
Wichita、Kansas、美国、67214
- 招聘中
- Wesley Medical Center
-
接触:
- Site Public Contact
- 电话号码:316-962-7802
- 邮箱:WesleyResearch@wesleymc.com
-
首席研究员:
- Nathan S. Hall
-
-
Kentucky
-
Lexington、Kentucky、美国、40536
- 招聘中
- University of Kentucky/Markey Cancer Center
-
接触:
- Site Public Contact
- 电话号码:859-257-3379
-
首席研究员:
- James T. Badgett
-
Louisville、Kentucky、美国、40202
- 招聘中
- Norton Children's Hospital
-
接触:
- Site Public Contact
- 电话号码:502-629-5500
- 邮箱:CancerResource@nortonhealthcare.org
-
首席研究员:
- Michael J. Ferguson
-
-
Louisiana
-
New Orleans、Louisiana、美国、70118
- 招聘中
- Children's Hospital New Orleans
-
首席研究员:
- Maria C. Velez-Yanguas
-
接触:
- Site Public Contact
- 电话号码:504-894-5377
-
-
Maine
-
Bangor、Maine、美国、04401
- 招聘中
- Eastern Maine Medical Center
-
接触:
- Site Public Contact
- 电话号码:207-973-4274
-
首席研究员:
- Daniel L. Callaway
-
Scarborough、Maine、美国、04074
- 招聘中
- Maine Children's Cancer Program
-
首席研究员:
- Sei-Gyung K. Sze
-
接触:
- Site Public Contact
- 电话号码:207-396-8670
- 邮箱:clinicalresearch@mainehealth.org
-
-
Maryland
-
Baltimore、Maryland、美国、21287
- 招聘中
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
首席研究员:
- Allen R. Chen
-
接触:
- Site Public Contact
- 电话号码:410-955-8804
- 邮箱:jhcccro@jhmi.edu
-
Baltimore、Maryland、美国、21215
- 招聘中
- Sinai Hospital of Baltimore
-
首席研究员:
- Jason M. Fixler
-
接触:
- Site Public Contact
- 电话号码:410-601-9083
-
Baltimore、Maryland、美国、21201
- 招聘中
- University of Maryland/Greenebaum Cancer Center
-
接触:
- Site Public Contact
- 电话号码:800-888-8823
-
首席研究员:
- Teresa A. York
-
Bethesda、Maryland、美国、20889-5600
- 招聘中
- Walter Reed National Military Medical Center
-
接触:
- Site Public Contact
- 电话号码:301-319-2100
-
首席研究员:
- Kip R. Hartman
-
-
Massachusetts
-
Boston、Massachusetts、美国、02114
- 招聘中
- Massachusetts General Hospital Cancer Center
-
接触:
- Site Public Contact
- 电话号码:877-726-5130
-
首席研究员:
- Lauren H. Boal
-
Boston、Massachusetts、美国、02215
- 招聘中
- Dana-Farber Cancer Institute
-
接触:
- Site Public Contact
- 电话号码:877-442-3324
-
首席研究员:
- Suzanne Shusterman
-
-
Michigan
-
Ann Arbor、Michigan、美国、48109
- 招聘中
- C S Mott Children's Hospital
-
接触:
- Site Public Contact
- 电话号码:800-865-1125
-
首席研究员:
- Rajen Mody
-
Detroit、Michigan、美国、48201
- 暂停
- Children's Hospital of Michigan
-
Grand Rapids、Michigan、美国、49503
- 招聘中
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
-
接触:
- Site Public Contact
- 电话号码:616-391-1230
- 邮箱:crcwm-regulatory@crcwm.org
-
首席研究员:
- Kathleen Y. Butler
-
Kalamazoo、Michigan、美国、49007
- 招聘中
- Bronson Methodist Hospital
-
接触:
- Site Public Contact
- 电话号码:616-391-1230
- 邮箱:crcwm-regulatory@crcwm.org
-
首席研究员:
- Kathleen Y. Butler
-
Royal Oak、Michigan、美国、48073
- 招聘中
- Corewell Health Children's
-
接触:
- Site Public Contact
- 电话号码:248-551-7695
-
首席研究员:
- Marie V. Nelson
-
-
Minnesota
-
Minneapolis、Minnesota、美国、55404
- 招聘中
- Children's Hospitals and Clinics of Minnesota - Minneapolis
-
首席研究员:
- Michael K. Richards
-
接触:
- Site Public Contact
- 电话号码:612-813-5913
- 邮箱:pauline.mitby@childrensmn.org
-
Minneapolis、Minnesota、美国、55455
- 招聘中
- University of Minnesota/Masonic Cancer Center
-
接触:
- Site Public Contact
- 电话号码:612-624-2620
-
首席研究员:
- Robin L. Williams
-
Rochester、Minnesota、美国、55905
- 招聘中
- Mayo Clinic in Rochester
-
接触:
- Site Public Contact
- 电话号码:855-776-0015
-
首席研究员:
- Peter Schoettler
-
-
Mississippi
-
Jackson、Mississippi、美国、39216
- 招聘中
- University of Mississippi Medical Center
-
接触:
- Site Public Contact
- 电话号码:601-815-6700
-
首席研究员:
- Amanda Strobel
-
-
Missouri
-
Columbia、Missouri、美国、65212
- 招聘中
- University of Missouri Children's Hospital
-
首席研究员:
- Barbara A. Gruner
-
接触:
- Site Public Contact
- 电话号码:573-882-1960
- 邮箱:snwq62@health.missouri.edu
-
Kansas City、Missouri、美国、64108
- 招聘中
- Children's Mercy Hospitals and Clinics
-
首席研究员:
- Keith J. August
-
接触:
- Site Public Contact
- 电话号码:816-302-6808
- 邮箱:COGResearchGroup@cmh.edu
-
St Louis、Missouri、美国、63110
- 招聘中
- Washington University School of Medicine
-
接触:
- Site Public Contact
- 电话号码:800-600-3606
- 邮箱:info@siteman.wustl.edu
-
首席研究员:
- Frederick S. Huang
-
St Louis、Missouri、美国、63141
- 招聘中
- Mercy Hospital Saint Louis
-
接触:
- Site Public Contact
- 电话号码:314-251-7066
-
首席研究员:
- Robin D. Hanson
-
-
Nebraska
-
Omaha、Nebraska、美国、68114
- 招聘中
- Children's Hospital and Medical Center of Omaha
-
接触:
- Site Public Contact
- 电话号码:402-955-3949
-
首席研究员:
- Jill C. Beck
-
Omaha、Nebraska、美国、68198
- 招聘中
- University of Nebraska Medical Center
-
接触:
- Site Public Contact
- 电话号码:402-559-6941
- 邮箱:unmcrsa@unmc.edu
-
首席研究员:
- Jill C. Beck
-
-
Nevada
-
Las Vegas、Nevada、美国、89135
- 招聘中
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation
-
接触:
- Site Public Contact
- 电话号码:702-384-0013
- 邮箱:research@sncrf.org
-
首席研究员:
- Joseph L. Lasky
-
-
New Hampshire
-
Lebanon、New Hampshire、美国、03756
- 招聘中
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
首席研究员:
- Angela Ricci
-
接触:
- Site Public Contact
- 电话号码:800-639-6918
- 邮箱:cancer.research.nurse@dartmouth.edu
-
-
New Jersey
-
Hackensack、New Jersey、美国、07601
- 招聘中
- Hackensack University Medical Center
-
首席研究员:
- Katharine Offer
-
接触:
- Site Public Contact
- 电话号码:551-996-2897
-
Morristown、New Jersey、美国、07960
- 招聘中
- Morristown Medical Center
-
接触:
- Site Public Contact
- 电话号码:973-971-5900
-
首席研究员:
- Kathryn L. Laurie
-
New Brunswick、New Jersey、美国、08901
- 招聘中
- Saint Peter's University Hospital
-
首席研究员:
- Nibal A. Zaghloul
-
接触:
- Site Public Contact
- 电话号码:732-745-8600
- 邮箱:officeofresearch@saintpetersuh.com
-
New Brunswick、New Jersey、美国、08903
- 招聘中
- Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
-
接触:
- Site Public Contact
- 电话号码:732-235-8675
-
首席研究员:
- Nehal S. Parikh
-
Newark、New Jersey、美国、07112
- 招聘中
- Newark Beth Israel Medical Center
-
接触:
- Site Public Contact
- 电话号码:973-926-7230
- 邮箱:Christine.Kosmides@rwjbh.org
-
首席研究员:
- Teena Bhatla
-
Paterson、New Jersey、美国、07503
- 招聘中
- Saint Joseph's Regional Medical Center
-
接触:
- Site Public Contact
- 电话号码:973-754-2207
- 邮箱:HallL@sjhmc.org
-
首席研究员:
- Alissa Kahn
-
-
New Mexico
-
Albuquerque、New Mexico、美国、87106
- 暂停
- University of New Mexico Cancer Center
-
-
New York
-
Albany、New York、美国、12208
- 招聘中
- Albany Medical Center
-
接触:
- Site Public Contact
- 电话号码:518-262-5513
-
首席研究员:
- Lauren R. Weintraub
-
Buffalo、New York、美国、14263
- 招聘中
- Roswell Park Cancer Institute
-
接触:
- Site Public Contact
- 电话号码:800-767-9355
- 邮箱:askroswell@roswellpark.org
-
首席研究员:
- Clare J. Twist
-
Mineola、New York、美国、11501
- 招聘中
- NYU Langone Hospital - Long Island
-
接触:
- Site Public Contact
- 电话号码:212-263-4432
- 邮箱:cancertrials@nyulangone.org
-
首席研究员:
- Chana L. Glasser
-
New Hyde Park、New York、美国、11040
- 招聘中
- The Steven and Alexandra Cohen Children's Medical Center of New York
-
接触:
- Site Public Contact
- 电话号码:718-470-3460
-
首席研究员:
- Julie I. Krystal
-
New York、New York、美国、10032
- 招聘中
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
首席研究员:
- Nobuko Hijiya
-
接触:
- Site Public Contact
- 电话号码:212-342-5162
- 邮箱:cancerclinicaltrials@cumc.columbia.edu
-
New York、New York、美国、10016
- 招聘中
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
首席研究员:
- Elizabeth A. Raetz
-
接触:
- Site Public Contact
- 邮箱:CancerTrials@nyulangone.org
-
Rochester、New York、美国、14642
- 招聘中
- University of Rochester
-
接触:
- Site Public Contact
- 电话号码:585-275-5830
-
首席研究员:
- Rafi R. Kazi
-
Syracuse、New York、美国、13210
- 招聘中
- State University of New York Upstate Medical University
-
接触:
- Site Public Contact
- 电话号码:315-464-5476
-
首席研究员:
- Melanie A. Comito
-
The Bronx、New York、美国、10467
- 招聘中
- Montefiore Medical Center - Moses Campus
-
接触:
- Site Public Contact
- 电话号码:718-379-6866
- 邮箱:eskwak@montefiore.org
-
首席研究员:
- Alice Lee
-
Valhalla、New York、美国、10595
- 招聘中
- New York Medical College
-
接触:
- Site Public Contact
- 电话号码:914-594-3794
-
首席研究员:
- Andrew J. Bellantoni
-
-
North Carolina
-
Asheville、North Carolina、美国、28801
- 招聘中
- Mission Hospital
-
接触:
- Site Public Contact
- 电话号码:828-213-7055
- 邮箱:NCDV.ResearchRegulatory@HCAHealthcare.com
-
首席研究员:
- Douglas J. Scothorn
-
Chapel Hill、North Carolina、美国、27599
- 招聘中
- UNC Lineberger Comprehensive Cancer Center
-
接触:
- Site Public Contact
- 电话号码:877-668-0683
- 邮箱:cancerclinicaltrials@med.unc.edu
-
首席研究员:
- Thomas B. Alexander
-
Charlotte、North Carolina、美国、28203
- 招聘中
- Carolinas Medical Center/Levine Cancer Institute
-
接触:
- Site Public Contact
- 电话号码:800-804-9376
-
首席研究员:
- Joel A. Kaplan
-
Charlotte、North Carolina、美国、28204
- 招聘中
- Novant Health Presbyterian Medical Center
-
接触:
- Site Public Contact
- 电话号码:980-201-6360
- 邮箱:kashah@novanthealth.org
-
首席研究员:
- Holly Edington
-
Durham、North Carolina、美国、27710
- 招聘中
- Duke University Medical Center
-
首席研究员:
- Jessica M. Sun
-
接触:
- Site Public Contact
- 电话号码:888-275-3853
-
Greenville、North Carolina、美国、27834
- 招聘中
- East Carolina University
-
接触:
- Site Public Contact
- 电话号码:252-744-1015
- 邮箱:eubankss@ecu.edu
-
首席研究员:
- Andrea R. Whitfield
-
Winston-Salem、North Carolina、美国、27157
- 招聘中
- Wake Forest University Health Sciences
-
接触:
- Site Public Contact
- 电话号码:336-713-6771
-
首席研究员:
- Sarah Supples
-
-
North Dakota
-
Fargo、North Dakota、美国、58122
- 招聘中
- Sanford Broadway Medical Center
-
接触:
- Site Public Contact
- 电话号码:701-323-5760
- 邮箱:OncologyClinicalTrialsFargo@sanfordhealth.org
-
首席研究员:
- Samuel J. Milanovich
-
-
Ohio
-
Akron、Ohio、美国、44308
- 招聘中
- Children's Hospital Medical Center of Akron
-
接触:
- Site Public Contact
- 电话号码:330-543-3193
-
首席研究员:
- Lauren R. Draper
-
Cincinnati、Ohio、美国、45229
- 招聘中
- Cincinnati Children's Hospital Medical Center
-
接触:
- Site Public Contact
- 电话号码:513-636-2799
- 邮箱:cancer@cchmc.org
-
首席研究员:
- Katherine M. Somers
-
Cleveland、Ohio、美国、44195
- 招聘中
- Cleveland Clinic Foundation
-
接触:
- Site Public Contact
- 电话号码:866-223-8100
- 邮箱:TaussigResearch@ccf.org
-
首席研究员:
- Matteo M. Trucco
-
Cleveland、Ohio、美国、44106
- 招聘中
- Rainbow Babies and Childrens Hospital
-
接触:
- Site Public Contact
- 电话号码:216-844-5437
-
首席研究员:
- Duncan S. Stearns
-
Columbus、Ohio、美国、43205
- 招聘中
- Nationwide Children's Hospital
-
接触:
- Site Public Contact
- 电话号码:614-722-6039
- 邮箱:Melinda.Triplet@nationwidechildrens.org
-
首席研究员:
- Mark A. Ranalli
-
Dayton、Ohio、美国、45404
- 招聘中
- Dayton Children's Hospital
-
接触:
- Site Public Contact
- 电话号码:800-228-4055
-
首席研究员:
- Jordan M. Wright
-
Toledo、Ohio、美国、43606
- 招聘中
- ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital
-
接触:
- Site Public Contact
- 电话号码:419-824-1842
- 邮箱:PCIOncResearch@promedica.org
-
首席研究员:
- Jamie L. Dargart
-
-
Oklahoma
-
Oklahoma City、Oklahoma、美国、73104
- 招聘中
- University of Oklahoma Health Sciences Center
-
接触:
- Site Public Contact
- 电话号码:405-271-8777
- 邮箱:ou-clinical-trials@ouhsc.edu
-
首席研究员:
- Rene Y. McNall-Knapp
-
Tulsa、Oklahoma、美国、74136
- 招聘中
- Saint Francis Children's Hospital
-
首席研究员:
- Jill A. Salo
-
接触:
- Site Public Contact
- 电话号码:918-502-6720
-
-
Oregon
-
Portland、Oregon、美国、97227
- 招聘中
- Legacy Emanuel Children's Hospital
-
接触:
- Site Public Contact
- 电话号码:503-413-2560
-
首席研究员:
- Jason M. Glover
-
Portland、Oregon、美国、97239
- 招聘中
- Oregon Health and Science University
-
接触:
- Site Public Contact
- 电话号码:503-494-1080
- 邮箱:trials@ohsu.edu
-
首席研究员:
- Susan J. Lindemulder
-
-
Pennsylvania
-
Allentown、Pennsylvania、美国、18103
- 招聘中
- Lehigh Valley Hospital-Cedar Crest
-
接触:
- Site Public Contact
- 电话号码:610-402-9543
- 邮箱:Morgan_M.Horton@lvhn.org
-
首席研究员:
- Jacob A. Troutman
-
Danville、Pennsylvania、美国、17822
- 招聘中
- Geisinger Medical Center
-
首席研究员:
- Jagadeesh Ramdas
-
接触:
- Site Public Contact
- 电话号码:570-271-5251
- 邮箱:cancerresearch@geisinger.edu
-
Philadelphia、Pennsylvania、美国、19104
- 招聘中
- Children's Hospital of Philadelphia
-
首席研究员:
- Rochelle Bagatell
-
接触:
- Site Public Contact
- 电话号码:267-425-5544
- 邮箱:CancerTrials@email.chop.edu
-
Philadelphia、Pennsylvania、美国、19134
- 招聘中
- Saint Christopher's Hospital for Children
-
接触:
- Site Public Contact
- 电话号码:215-427-8991
-
首席研究员:
- Gregory E. Halligan
-
Pittsburgh、Pennsylvania、美国、15224
- 招聘中
- Children's Hospital of Pittsburgh of UPMC
-
接触:
- Site Public Contact
- 电话号码:412-692-8570
- 邮箱:jean.tersak@chp.edu
-
首席研究员:
- Jean M. Tersak
-
-
Rhode Island
-
Providence、Rhode Island、美国、02903
- 招聘中
- Rhode Island Hospital
-
首席研究员:
- Bradley DeNardo
-
接触:
- Site Public Contact
- 电话号码:401-444-1488
-
-
South Carolina
-
Charleston、South Carolina、美国、29425
- 招聘中
- Medical University of South Carolina
-
接触:
- Site Public Contact
- 电话号码:843-792-9321
- 邮箱:hcc-clinical-trials@musc.edu
-
首席研究员:
- Jacqueline M. Kraveka
-
Columbia、South Carolina、美国、29203
- 招聘中
- Prisma Health Richland Hospital
-
首席研究员:
- Stuart L. Cramer
-
接触:
- Site Public Contact
- 电话号码:864-522-4317
- 邮箱:Kim.Williams3@prismahealth.org
-
Greenville、South Carolina、美国、29605
- 招聘中
- BI-LO Charities Children's Cancer Center
-
首席研究员:
- Aniket Saha
-
接触:
- Site Public Contact
- 电话号码:864-522-4317
- 邮箱:Kim.Williams3@prismahealth.org
-
-
South Dakota
-
Sioux Falls、South Dakota、美国、57117-5134
- 招聘中
- Sanford USD Medical Center - Sioux Falls
-
接触:
- Site Public Contact
- 电话号码:605-312-3320
- 邮箱:OncologyClinicalTrialsSF@SanfordHealth.org
-
首席研究员:
- Jordan Fritch-Hanson
-
-
Tennessee
-
Knoxville、Tennessee、美国、37916
- 招聘中
- East Tennessee Childrens Hospital
-
接触:
- Site Public Contact
- 电话号码:865-541-8266
-
首席研究员:
- Susan E. Spiller
-
Memphis、Tennessee、美国、38105
- 招聘中
- Saint Jude Children's Research Hospital
-
首席研究员:
- Sara M. Federico
-
接触:
- Site Public Contact
- 电话号码:888-226-4343
- 邮箱:referralinfo@stjude.org
-
Nashville、Tennessee、美国、37232
- 招聘中
- Vanderbilt University/Ingram Cancer Center
-
首席研究员:
- Daniel J. Benedetti
-
接触:
- Site Public Contact
- 电话号码:800-811-8480
-
Nashville、Tennessee、美国、37203
- 招聘中
- The Children's Hospital at TriStar Centennial
-
接触:
- Site Public Contact
- 电话号码:615-342-1919
-
首席研究员:
- Clinton M. Carroll
-
-
Texas
-
Austin、Texas、美国、78723
- 招聘中
- Dell Children's Medical Center of Central Texas
-
接触:
- Site Public Contact
- 电话号码:512-628-1902
- 邮箱:TXAUS-DL-SFCHemonc.research@ascension.org
-
首席研究员:
- Shannon M. Cohn
-
Corpus Christi、Texas、美国、78411
- 招聘中
- Driscoll Children's Hospital
-
接触:
- Site Public Contact
- 电话号码:361-694-5311
- 邮箱:Crystal.DeLosSantos@dchstx.org
-
首席研究员:
- Nkechi I. Mba
-
Dallas、Texas、美国、75390
- 招聘中
- UT Southwestern/Simmons Cancer Center-Dallas
-
首席研究员:
- Tanya C. Watt
-
接触:
- Site Public Contact
- 电话号码:214-648-7097
- 邮箱:canceranswerline@UTSouthwestern.edu
-
Dallas、Texas、美国、75230
- 招聘中
- Medical City Dallas Hospital
-
接触:
- Site Public Contact
- 电话号码:972-566-5588
-
首席研究员:
- Maurizio L. Ghisoli
-
El Paso、Texas、美国、79905
- 招聘中
- El Paso Children's Hospital
-
接触:
- Site Public Contact
- 电话号码:915-298-5444
- 邮箱:ranjan.bista@ttuhsc.edu
-
首席研究员:
- Benjamin Carcamo
-
Fort Worth、Texas、美国、76104
- 招聘中
- Cook Children's Medical Center
-
接触:
- Site Public Contact
- 电话号码:682-885-2103
- 邮箱:CookChildrensResearch@cookchildrens.org
-
首席研究员:
- Chelsee Greer
-
Houston、Texas、美国、77030
- 招聘中
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
接触:
- Site Public Contact
- 电话号码:713-798-1354
- 邮箱:burton@bcm.edu
-
首席研究员:
- Jennifer H. Foster
-
Houston、Texas、美国、77030
- 招聘中
- UT MD Anderson Cancer Center
-
接触:
- Site Public Contact
- 电话号码:866-632-6789
- 邮箱:askmdanderson@mdanderson.org
-
首席研究员:
- Najat C. Daw
-
Lubbock、Texas、美国、79410
- 招聘中
- Covenant Children's Hospital
-
首席研究员:
- Kishor M. Bhende
-
接触:
- Site Public Contact
- 电话号码:806-725-8657
- 邮箱:mbisbee@providence.org
-
Lubbock、Texas、美国、79415
- 招聘中
- UMC Cancer Center / UMC Health System
-
接触:
- Site Public Contact
- 电话号码:806-775-8590
-
首席研究员:
- Erin K. Barr
-
San Antonio、Texas、美国、78207
- 招聘中
- Children's Hospital of San Antonio
-
接触:
- Site Public Contact
- 电话号码:210-704-2894
- 邮箱:bridget.medina@christushealth.org
-
首席研究员:
- Julie Voeller
-
San Antonio、Texas、美国、78229
- 招聘中
- University of Texas Health Science Center at San Antonio
-
接触:
- Site Public Contact
- 电话号码:210-450-3800
- 邮箱:phoresearchoffice@uthscsa.edu
-
首席研究员:
- Aaron J. Sugalski
-
San Antonio、Texas、美国、78229
- 招聘中
- Methodist Children's Hospital of South Texas
-
接触:
- Site Public Contact
- 电话号码:210-575-6240
- 邮箱:Vinod.GidvaniDiaz@hcahealthcare.com
-
首席研究员:
- Jose M. Esquilin
-
-
Utah
-
Salt Lake City、Utah、美国、84113
- 招聘中
- Primary Children's Hospital
-
接触:
- Site Public Contact
- 电话号码:801-585-5270
-
首席研究员:
- Leonora R. Slatnick
-
-
Vermont
-
Burlington、Vermont、美国、05405
- 招聘中
- University of Vermont and State Agricultural College
-
接触:
- Site Public Contact
- 电话号码:802-656-8990
- 邮箱:rpo@uvm.edu
-
首席研究员:
- Jessica L. Heath
-
-
Virginia
-
Charlottesville、Virginia、美国、22908
- 招聘中
- University of Virginia Cancer Center
-
接触:
- Site Public Contact
- 电话号码:434-243-6303
- 邮箱:uvacancertrials@hscmail.mcc.virginia.edu
-
首席研究员:
- Brian C. Belyea
-
Portsmouth、Virginia、美国、23708-2197
- 招聘中
- Naval Medical Center - Portsmouth
-
接触:
- Site Public Contact
- 电话号码:757-953-5939
-
首席研究员:
- Karin Brockman
-
-
Washington
-
Seattle、Washington、美国、98105
- 招聘中
- Seattle Children's Hospital
-
接触:
- Site Public Contact
- 电话号码:866-987-2000
-
首席研究员:
- Sarah E. Leary
-
Spokane、Washington、美国、99204
- 招聘中
- Providence Sacred Heart Medical Center and Children's Hospital
-
接触:
- Site Public Contact
- 电话号码:800-228-6618
- 邮箱:HopeBeginsHere@providence.org
-
首席研究员:
- Judy L. Felgenhauer
-
Tacoma、Washington、美国、98405
- 招聘中
- Mary Bridge Children's Hospital and Health Center
-
接触:
- Site Public Contact
- 电话号码:253-403-1461
- 邮箱:research@multicare.org
-
首席研究员:
- Robert G. Irwin
-
-
West Virginia
-
Huntington、West Virginia、美国、25701
- 招聘中
- Edwards Comprehensive Cancer Center
-
首席研究员:
- Mark A. Ranalli
-
接触:
- Site Public Contact
- 电话号码:304-399-6566
- 邮箱:Christina.Cole@chhi.org
-
Morgantown、West Virginia、美国、26506
- 招聘中
- West Virginia University Healthcare
-
接触:
- Site Public Contact
- 电话号码:304-293-7374
- 邮箱:cancertrialsinfo@hsc.wvu.edu
-
首席研究员:
- Ashley E. Meyer
-
-
Wisconsin
-
Green Bay、Wisconsin、美国、54301
- 暂停
- Saint Vincent Hospital Cancer Center Green Bay
-
Madison、Wisconsin、美国、53792
- 招聘中
- University of Wisconsin Carbone Cancer Center - University Hospital
-
接触:
- Site Public Contact
- 电话号码:800-622-8922
- 邮箱:clinicaltrials@cancer.wisc.edu
-
首席研究员:
- Margo L. Hoover-Regan
-
Marshfield、Wisconsin、美国、54449
- 招聘中
- Marshfield Medical Center-Marshfield
-
接触:
- Site Public Contact
- 电话号码:800-782-8581
- 邮箱:oncology.clinical.trials@marshfieldresearch.org
-
首席研究员:
- Michelle A. Manalang
-
Milwaukee、Wisconsin、美国、53226
- 招聘中
- Children's Hospital of Wisconsin
-
首席研究员:
- Angela Steineck
-
接触:
- Site Public Contact
- 电话号码:414-955-4727
- 邮箱:MACCCTO@mcw.edu
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Patients must be enrolled on APEC14B1 and have consented to testing through the Molecular Characterization Initiative (MCI), prior to enrollment on ANBL2131
-
≤ 30 years at the time of initial diagnosis with high-risk disease
-
* Must have a diagnosis of neuroblastoma (NBL) or ganglioneuroblastoma (nodular) verified by tumor pathology analysis or demonstration of clumps of tumor cells in bone marrow with elevated urinary catecholamines
-
Newly diagnosed, high risk neuroblastoma (HRNBL) defined as one of the following:
- Any age with International Neuroblastoma Risk Group (INRG) Stage L2, MS, or M and MYCN amplification
- Age ≥ 547 days and INRG stage M regardless of biologic features (clinical MYCN testing not required prior to enrollment)
- Any age initially diagnosed with INRG Stage L1 MYCN amplified NBL who have progressed to stage M without systemic chemotherapy
- Age ≥ 547 days of age initially diagnosed with INRG Stage L1, L2, or MS who have progressed to stage M without systemic chemotherapy (clinical MYCN testing not required prior to enrollment)
-
-
Patients must have a body surface area (BSA) ≥ 0.25 m^2
-
No prior anti-cancer therapy except as outlined below:
- Patients initially recognized to have high-risk disease treated with topotecan/cyclophosphamide initiated on an emergent basis and within allowed timing, and with consent
- Patients observed or treated with a single cycle of chemotherapy per a low or intermediate risk neuroblastoma regimen (e.g., as per ANBL0531, ANBL1232 or similar) for what initially appeared to be non-high-risk disease but subsequently found to meet the criteria
- Patients who received localized emergency radiation to sites of life threatening or function-threatening disease prior to or immediately after establishment of the definitive diagnosis
-
Human immunodeficiency virus (HIV) -infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
-
A serum creatinine based on age/sex as follows:
-
1 month to < 6 months: Male 0.4 mg/dL and female 0.4mg/dL
-
6 months to < 1 year: Male 0.5 mg/dL and female 0.5 mg/dL
-
1 to < 2 years: Male 0.6 mg/dL and female 0.6 mg/dL
-
2 to < 6 years: Male 0.8 mg/dL and female 0.8 mg/dL
-
6 to < 10 years: Male 1 mg/dL and female 1 mg/dL
-
10 to < 13 years: Male 1.2 mg/dL and female 1.2 mg/dL
-
13 to < 16 years: Male 1.5 mg/dL and female 1.4 mg/dL
-
≥ 16 years: Male 1.7 mg/dL and female 1.4 mg/dL
- The threshold creatinine values were derived from the Schwartz formula for estimating glomerular filtration rate (GFR) utilizing child length and stature data published by the Centers for Disease Control (CDC)
-
or a 24-hour urine creatinine clearance ≥ 70 mL/min/1.73 m^2 or
-
or a GFR ≥ 70 mL/min/1.73 m^2. GFR must be performed using direct measurement with a nuclear blood sampling method or direct small molecule clearance method (iothalamate or other molecule per institutional standard)
- Note: Estimated GFR (eGFR) from serum creatinine, cystatin C or other estimates are not acceptable for determining eligibility
-
-
Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age
-
Serum glutamic pyruvic transaminase (SGPT) (Alanine aminotransferase [ALT]) ≤ 10 x ULN*
- Note: For the purpose of this study, the ULN for SGPT (ALT) has been set to the value of 45 U/L
-
* Shortening fraction of ≥ 27% by echocardiogram, or
- Ejection fraction of ≥ 50% by echocardiogram or radionuclide angiogram
-
Ability to tolerate Peripheral Blood Stem Cell (PBSC) collection:
No known contraindication to PBSC collection. Examples of contraindications might be a weight or size less than the collecting institution finds feasible, or a physical condition that would limit the ability of the child to undergo apheresis catheter placement (if necessary) and/or the apheresis procedure
Exclusion Criteria:
- Patients who are 365-546 days of age with INRG Stage M and MYCN non-amplified NBL, irrespective of additional biologic features
- Patients ≥ 547 days of age with INRG Stage L2, MYCN non-amplified NBL, regardless of additional biologic features
- Patients with known bone marrow failure syndromes
- Patients on chronic immunosuppressive medications (e.g., tacrolimus, cyclosporine, corticosteroids) for reasons other than prevention/treatment of allergic reactions and adrenal replacement therapy are not eligible. Topical and inhaled corticosteroids are acceptable
- Patients with a primary immunodeficiency syndrome who require ongoing immune globulin replacement therapy
- Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs. A pregnancy test is required prior to enrollment for female patients of childbearing potential
- Lactating females who plan to breastfeed their infants
- Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation
- All patients and/or their parents or legal guardians must sign a written informed consent
- All institutional, food and drug administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器:Arm A (SOC treatment)
See detailed description |
Given IV
其他名称:
Given IV
其他名称:
Given IV
其他名称:
Undergo bone marrow biopsy
其他名称:
Given IV
其他名称:
Given IV
其他名称:
Undergo MRI
其他名称:
Undergo ECHO
其他名称:
Undergo MUGA
其他名称:
Undergo bone marrow aspiration Given IV
其他名称:
Undergo CT scan
其他名称:
Given IV
其他名称:
Undergo radiation therapy
其他名称:
Undergo blood and urine sample collection
其他名称:
Ancillary studies Given IV
其他名称:
Given IV Given IV
其他名称:
Given IV
其他名称:
Undergo FDG PET
其他名称:
Undergo stem cell infusion
其他名称:
Given PO
其他名称:
Undergo apheresis
其他名称:
Undergo I-MIBG scan
其他名称:
Given PO or via NG or G tube
其他名称:
Undergo tumor resection surgery |
|
实验性的:Arm B (Dinutuximab in induction)
See detailed description |
Given IV
其他名称:
Given IV
其他名称:
Given IV
其他名称:
Undergo bone marrow biopsy
其他名称:
Given IV
其他名称:
Given IV
其他名称:
Undergo MRI
其他名称:
Undergo ECHO
其他名称:
Undergo MUGA
其他名称:
Undergo bone marrow aspiration Given IV
其他名称:
Undergo CT scan
其他名称:
Given IV
其他名称:
Undergo radiation therapy
其他名称:
Undergo blood and urine sample collection
其他名称:
Ancillary studies Given IV
其他名称:
Given IV Given IV
其他名称:
Given IV
其他名称:
Undergo FDG PET
其他名称:
Undergo stem cell infusion
其他名称:
Given PO
其他名称:
Undergo apheresis
其他名称:
Undergo I-MIBG scan
其他名称:
Given PO or via NG or G tube
其他名称:
Undergo tumor resection surgery |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Event free survival (EFS)
大体时间:Up to 3 years
|
EFS time is calculated from time of randomization to Arms A or B to first episode of disease relapse or progression, second malignancy, or death, or until last contact if no event has occurred. |
Up to 3 years
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
End of Induction (EOI) response rate
大体时间:From randomization to end of extended Induction, up to 12 months
|
The response rate will be calculated among all evaluable patients at end of Induction. Responders are defined as patients who achieve a >= partial response per the revised 2017 International Neuroblastoma Response Criteria (INRC) |
From randomization to end of extended Induction, up to 12 months
|
|
Overall survival (OS)
大体时间:Up to 3 years
|
OS time is calculated from time of randomization to Arms A or B until death, or until last contact if patient is alive. |
Up to 3 years
|
|
Incidence of adverse events
大体时间:Up to 2 years
|
The proportion of patients with at least one grade 3 or higher non-hematologic toxicity or grade 4 or higher hematologic toxicity during protocol therapy, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0, will be reported. |
Up to 2 years
|
|
GD2 expression
大体时间:Up to 12 months
|
Dinutuximab binding to pre-therapy patient tumor samples will be measured and categorized as high or low. |
Up to 12 months
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Association between tumor and host factors and outcomes
大体时间:Up to 10 years
|
A series of univariate and multivariate Cox proportional hazards (for EFS and OS) and logistic regression (for responders vs. non-responders) models will be fit for patients in Arms A and B to evaluate the relationship between tumor and host factors (including tumor ALK and other somatic mutations, copy-number aberrations, gene fusions, gene expression, and pathogenic germline variants) and chemo-immunotherapy during Induction with outcome. |
Up to 10 years
|
|
Circulating biomarkers and markers of minimal residual disease
大体时间:Up to 10 years
|
Will be assessed by comparing the proportion of patients with detectable vs. non-detectable tumor markers (including circulating tumor deoxyribonucleic acid, circulating free DNA, circulating tumor cells, and immune function profiling) between Arms A and B during and after induction and post-consolidation therapy using chi-squared tests at each individual time point, and Cochran's Q across time points to determine if there is a consistent difference in proportions between arms across time. In addition, the tumor markers will be analyzed as continuous variables using longitudinal data analysis methodology such as mixed effects models or generalized estimating equations as appropriate. |
Up to 10 years
|
|
Patterns of failure
大体时间:Up to 10 years
|
The impact of early or late chemoimmunotherapy during Induction on the probability of the involvement of a specific disease site at first relapse will be evaluated using Fisher's exact test. |
Up to 10 years
|
|
Effect of telomere maintenance mechanisms
大体时间:Up to 10 years
|
A series of univariate and multivariate Cox proportional hazards (for EFS and OS) and logistic regression (for responders vs. non-responders) models will be fit for patients in arms A and B to evaluate the relationship between telomere maintenance mechanism and chemoimmunotherapy during Induction with outcome. Patients will be classified into 3 groups by telomere maintenance mechanism (TMM) based on messenger ribonucleic acid expression of TERT and analysis of telomeric DNA C-circles: telomerase (TERT) positive, alternative of lengthening of telomeres (ALT) positive, or no identified TMM. |
Up to 10 years
|
|
Functional and quality of life outcomes
大体时间:At serial time points during Induction, Extended Induction, Post-Consolidation, and at the end of therapy
|
Will descriptively summarize and compare the total Memorial Symptom Assessment Scale scores, total sub-domain scores, and individual symptom scores between patients randomized to receive dinutuximab during Induction (Arm B) to those of patients randomized to standard Induction (Arm A). |
At serial time points during Induction, Extended Induction, Post-Consolidation, and at the end of therapy
|
|
Adequacy of diagnostic biopsy specimens
大体时间:At time of tissue collection
|
Will be evaluated by descriptively comparing the successful delineation of histologic classification, MYCN amplification status, and ALK status via the traditional method of obtaining tissue for diagnosis, open surgical biopsy, versus the less invasive percutaneous core needle biopsy. |
At time of tissue collection
|
|
Associations between family-reported adverse social determinants of health and both clinical outcomes and biology
大体时间:Up to 10 years
|
Kaplan-Meier curves of EFS and OS will be generated and used to calculate 3-year EFS and OS estimates. Associations between social determinants of health (SDOH) and survival outcomes and time to receipt of dinutuximab will be evaluated with univariate and multivariate Cox proportional hazard models. Log-binomial regression will be used to estimate risk ratios and 95% CI for the occurrence of dinutuximab consent to randomization and therapy receipt by SDOH exposure. Effect modification of outcomes as a function of poverty, stratified by race/ethnicity, will be explored. |
Up to 10 years
|
|
Develop and validate deep learning predictors of Induction response (imaging objective)
大体时间:At diagnosis, EOI, during Extended Induction, and end of Extended Induction
|
Scans will be given as input to a convolutional neural network trained to predict EOI response. |
At diagnosis, EOI, during Extended Induction, and end of Extended Induction
|
|
Compare institutional versus central determination of overall response, individual response components, and PEIR and GEIR determination (imaging objective)
大体时间:Up to 10 years
|
Will be assessed by calculating the percentage of patients receiving the same EOI institutional and centrally reviewed determination of overall response, individual response components (primary tumor, soft tissue and bone metastatic disease, and bone marrow metastatic disease), and PEIR and GEIR. In addition, Cohen's kappa will be calculated to evaluate the concordance in each of these response measures. |
Up to 10 years
|
|
Incidence of late toxicities
大体时间:Up to 10 years
|
Will be addressed by calculating the proportion of treated patients with each late effect, including but not limited to impaired organ function, neuropsychiatric toxicity, and secondary malignancy. A 95% confidence interval will be placed on each proportion. |
Up to 10 years
|
|
Reduced dose radiotherapy to the primary site clinical target volume (CTV) in patients with complete response of the primary site at EOI results in comparable local control relative to historical cohorts
大体时间:Up to 10 years
|
The cumulative incidence of local progression (CILP) in patients with complete response of the primary site at EOI and GEIR on this study will be compared to the CILP rate of 11.2±1.8% observed on ANBL0532 using Gray's test. |
Up to 10 years
|
|
Post-transplant complications
大体时间:Up to 100 days post-transplant
|
Will be evaluated by calculating the incidence of endothelial injury complications and non-relapse mortality within 100 days of transplant, transplant-associated thrombotic microangiopathy (TA-TMA), severe TA-TMA, and sinusoidal obstruction syndrome (SOS) on Arms A and B and comparing between arms with a chi-squared test. The impact of TA-TMA occurrence on the timing or exclusion of subsequent therapy and interventions utilized to treat the TA-TMA, and associations with outcomes (EFS and OS) will be assessed. |
Up to 100 days post-transplant
|
|
Associations between end of induction (EOI) response and individual response components
大体时间:Up to 10 years
|
Log-rank tests will be used to explore the association between EOI response (using both the revised INRC and GEIR/PEIR classification) and individual response components (primary tumor, soft tissue and bone metastatic disease, and bone marrow metastatic disease) with outcome (EFS and OS). |
Up to 10 years
|
|
Changes in image-defined risk factors (IDRF)
大体时间:Up to 10 years
|
The proportion of patients in the analytic cohort for whom each particular IDRF and also the presence of any IDRF is absent prior to surgical resection will be computed. McNemar's test for paired observations will be applied to determine whether there is a difference in the proportion of each IDRF and any IDRF present before and after initial therapy, and conditional logistic regression will be used to compare between treatment arms A and B. The IDRF status after initial therapy and whether there has been a change from diagnosis will be associated with surgical outcome (complete vs. incomplete resection, presence or absence of surgical complications) using chi-squared tests, and compared between treatment arms A and B with the Cochran-Mantel-Haenszel test. The association of IDRF status with presence or absence of local failure after primary tumor resection will also be evaluated using a chi-squared test, and compared between treatment arms A and B with the Cochran-Mantel-Haenszel. |
Up to 10 years
|
合作者和调查者
调查人员
- 首席研究员:Sara M Federico、Children's Oncology Group
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
- 肿瘤
- 组织学类型的肿瘤
- 肿瘤、腺体和上皮
- 肿瘤,神经上皮
- 神经外胚层肿瘤
- 肿瘤、生殖细胞和胚胎
- 肿瘤,神经组织
- 神经外胚层肿瘤,原始的,外周的
- 神经外胚层肿瘤,原发性
- 成神经细胞瘤
- 神经节细胞瘤
- 组织和管理
- 卫生服务管理局
- 氨基酸,肽和蛋白质
- 有机化学品
- 杂环化合物,1形
- 杂环化合物
- 杂环化合物,2环
- 杂环化合物,融合环
- 调查技术
- 疗法
- 临床实验室技术
- 诊断技术和程序
- 诊断
- 手术程序,手术
- Azoles
- 细胞学技术
- 细胞诊断
- 视网膜类似
- 类胡萝卜素
- 多烯
- 烯烃
- 碳氢化合物,无环
- 碳氢化合物
- 环己烯
- 环己
- 环磷脂
- 碳氢化合物,Alicyclic
- 碳氢化合物,循环
- 萜烯
- 颜料,生物学
- 生物因素
- 碳水化合物
- 身体现象
- Camptothecin
- 生物碱
- Podophyllotoxin
- 四氢乙烯甲烯烃
- 萘
- 多环芳烃
- 碳氢化合物,芳香族
- 多环化合物
- 葡萄糖剂
- 糖苷
- 达卡巴嗪
- 三亚齐斯
- 咪唑
- 移植
- 吲哚
- 无机化学物质
- 氯化合物
- 氮化合物
- 协调配合物
- 氨基酸
- 元素
- 金属
- 诊断技术,手术
- 化学技术,分析
- 频谱分析
- 磷酰胺芥末
- 氮芥末化合物
- 芥末化合物
- 碳氢化合物,卤素
- 磷酰胺
- 有机磷化合物
- 金属,重
- VINCA生物碱
- Secologanin色素生物碱
- 吲哚生物碱
- 吲哚衍生物
- 吲哚王
- 蒽环类动物
- 萘烯
- 氨基糖苷
- 白金化合物
- Daunorubicin
- 过渡元素
- 细胞移植
- 基于细胞和组织的治疗
- 生物疗法
- 细胞置换
- 去除血液成分
- 白细胞减少程序
- 细胞分离
- 苯丙氨酸
- 氨基酸,芳香族
- 氨基酸,环状
- 医院管理
- 卫生设施管理
- 三乙基磷酰胺
- 阿祖里丁
- Azirines
- 泌尿外科手术程序
- 泌尿生殖器手术程序
- 替莫唑胺
- 伊立替康
- 环磷酰胺
- 马法兰
- 依托泊苷
- 卡铂
- 阿霉素
- 长春新碱
- 顺铂
- 异维A酸
- 噻替派
- 拓扑替康
- 1,2-二氨基环己烷柠檬酸铂 II
- 放疗
- 辐射
- 活检
- 标本处理
- 磁共振光谱
- 铂
- Dinutuximab
- 干细胞移植
- 造血干细胞移植
- 白细胞术
- 医院核医学系
- 膀胱尿道切除术
其他研究编号
- NCI-2023-08530
- U10CA180886 (美国 NIH 拨款/合同)
- NCI-2023-08530 (注册表标识符:CTRP (Clinical Trial Reporting Program))
- ANBL2131 (其他标识符:CTEP)
- ANBL2131 (其他标识符:Children's Oncology Group)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
"NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page."
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.